• Biosimilar Hyrimoz™ (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity ^†
• Biosimilars are critical to sustaining US healthcare system, providing broader access to vital treatments for prevalent chronic conditions such as psoriasis and rheumatoid arthritis, which affect over eight million Americans combined
• Hyrimozis third FDA-approved Sandoz biosimilar in US

 

Holzkirchen, Germany, October 31, 2018 — Sandoz, a Novartis division and the pioneer …